Last reviewed · How we verify

OnabotulinumtoxinA Injectable Product

University of Utah · FDA-approved active Small molecule

OnabotulinumtoxinA Injectable Product is a Botulinum toxin Small molecule drug developed by University of Utah. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox.

OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinumtoxinA Injectable Product
Also known asBotox
SponsorUniversity of Utah
Drug classBotulinum toxin
TargetSNAP-25 (synaptosomal-associated protein 25)
ModalitySmall molecule
Therapeutic areaNeurology, Dermatology, Ophthalmology
PhaseFDA-approved

Mechanism of action

The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in localized muscle weakness or paralysis that typically lasts 3-4 months. The effect is reversible as the body gradually regenerates new nerve terminals.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OnabotulinumtoxinA Injectable Product

What is OnabotulinumtoxinA Injectable Product?

OnabotulinumtoxinA Injectable Product is a Botulinum toxin drug developed by University of Utah, indicated for Cervical dystonia, Blepharospasm, Strabismus.

How does OnabotulinumtoxinA Injectable Product work?

OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is OnabotulinumtoxinA Injectable Product used for?

OnabotulinumtoxinA Injectable Product is indicated for Cervical dystonia, Blepharospasm, Strabismus, Chronic migraine, Severe primary axillary hyperhidrosis.

Who makes OnabotulinumtoxinA Injectable Product?

OnabotulinumtoxinA Injectable Product is developed and marketed by University of Utah (see full University of Utah pipeline at /company/university-of-utah).

Is OnabotulinumtoxinA Injectable Product also known as anything else?

OnabotulinumtoxinA Injectable Product is also known as Botox.

What drug class is OnabotulinumtoxinA Injectable Product in?

OnabotulinumtoxinA Injectable Product belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is OnabotulinumtoxinA Injectable Product in?

OnabotulinumtoxinA Injectable Product is FDA-approved (marketed).

What are the side effects of OnabotulinumtoxinA Injectable Product?

Common side effects of OnabotulinumtoxinA Injectable Product include Headache, Neck pain, Injection site pain, Muscle weakness, Eyelid ptosis, Dry mouth.

What does OnabotulinumtoxinA Injectable Product target?

OnabotulinumtoxinA Injectable Product targets SNAP-25 (synaptosomal-associated protein 25) and is a Botulinum toxin.

Related